|
WARNING:
Ethos Endymion Bright Eyes for cataracts was the actual product featured in
the Richard & Judy TV Trials and the Daily Mail newspaper features. Many
other eye drop suppliers are now trying to cash in on the phenomenal
success of our Bright Eyes drops and are exploiting our features,
testimonials and press coverage saying that they relate to their products
which is blatantly untrue! If it does not say Ethos Endymion Bright Eyes on
the Label then it is most definitely NOT the same product.
Purchasing these less expensive copy-cat products may lead you to very
disappointing results...
If you have a query, you will probably find the answer in our list of Frequently Asked Questions. 
|
N-Acetyl-Carnosine (NAC)
Bright Eyes Drops for pets melt away cataracts naturally! |
|
|
|
Ethos
Endymion Bright Eyes Drops for Pet Cataracts |
|
|
Maintaining their eye health is a
major concern as our pets age. As they get older their eyes have
a harder time fighting off free radicals that cause oxidative
stress. This highly oxidised environment within cells comes
about as a result of a chemical reaction from exposure to oxygen
and sunlight. Since the lens of the eye acts as a light shield
for the retina, it’s no wonder it takes all the oxidative
punishment. The destructive action of free radicals (they are
oxidising agents) also destroys enzymes that are needed to
maintain cellular metabolism. And, since blood flow decreases
with age, the eye is further deprived of other essential
nutrients for health.
Although many praise the benefits of dietary supplements,
another way of preventing and treating eye disorders is through
topical solutions.
Ethos Endymion Bright Eyes for pets is one of the most
advanced eye formulas that offer protection from free radicals
because of its unique formulation of lubricants, an anti-glycating
agent, and antioxidant. Glycation occurs as a result of
nonenzymatic binding of sugar to protein, which eventually leads
to tissue damage. It’s a condition that increases with age.
The newly formulated Endymion Bright Eyes for pets contains
1% N-Acetyl-L-Carnosine, a naturally occurring antioxidant and
anti-glycating agent that, when topically applied, can penetrate
and protect the lipid tissues of the eye against light damage.
Bright Eyes for pets will help to diminish free radical damage
and the harmful effects of glycosylation associated with
degenerative eye disease.
|
|
Bright Eyes For Pets
Ingredients: |
| |
Antioxidants: N-Acetyl-Carnosine
(NAC) - 1.0%
Glycerin (lubricant) - 1.0%
Carboxymethylcellulose sodium (lubricant) - 0.3%
Buffered with borates and potassium bicarbonate and as a
preservative
Sterile water (ophthalmic grade isotonic solution, pH 6.3 to
6.5)
Purified benzyl alcohol |
| |
|
|
|
Other Information: |
| |
Bright Eyes is 100% hypoallergenic
Bright Eyes for pets is 100% free of animal ingredients
Bright Eyes for Pets is 100% safe and suitable for use on most
pets and other animals |
|
| |
|
Bright Eyes For Pets
Recommended Usage: |
| |
The suggested use of Endymion Bright Eyes NAC Eye Drops for
Pets is to apply 1 to 2 drops in each eye every day. Those
whose pet has any kind of eye problem may want to apply 1 to
2 drops several times a day.
Each 5ml bottle should last 30 days at two drops per day or 15 days at four drops per day. A box contains 2 x 5ml bottles; therefore each
package can last between 30 and 60 days which represents
excellent value for money.
Unopened bottles should be stored in the dark in the refrigerator.
It is also recommended that you give 1 teaspoon of
Ethos élan vital for pets in powder form daily.
|
|
|
|
|
|
|
Use of Carnosine as an anti-senescence supplement
|
|
From our investigations,
we have reported that eye drops containing 20 mM carnosine were
used to treat 96 patients aged 60 years old having senile cataract
of various degrees of maturity, with the duration of the disease
from 2 to 21 years. The method is that after stopping all other
anti-cataract drugs, patients instilled 1-2 drops of the carnosine
containing solution in each eye 3-4 times each day for a period of
treatment ranging from 3-6 months. The level of eyesight
improvement and the change of lens transparency were considered as
an evaluation index of the curative effect of carnosine.
The result shows that
carnosine gives a profound effect on primary senile cataract, the
effective rate being 100%.
For mature senile cataract, the
effect rate is 80%, and positive effects were observed with other
types of cataract.
It is significant that no side
effect has been found in the observed cases. During recent years,
we have also applied carnosine drops containing the same content
to nearly 1,000 patients with senile cataract. Our research
findings (ready to be published) show similar results.
In addition, we applied
carnosine drops to patients aged 48-60 years with various degrees
of eyesight impairment but without symptoms of cataract. The
course of treatment is from 2 to 6 months. The results demonstrate
that carnosine appears to alleviate eye tiredness and
comparatively improve eyesight (obviously improve eyesight, giving
more clear vision). Subjects reported that carnosine could
brighten and relax their eyes.
It is an important point that
all the above research on the medical application of carnosine has
statistical significance.
|
|
|
| |
|
Efficacy
of N-acetylcarnosine in the treatment of cataracts: |
|
Babizhayev MA, Deyev AI, Yermakova VN, Semiletov YA, Davydova
NG, Doroshenko VS, Zhukotskii AV, Goldman IM.
PURPOSE: To evaluate the
effects of 1% N-acetylcarnosine (NAC) solution on lens clarity
over 6 and 24 months in patients with cataracts. TRIAL DESIGN:
Randomised, placebo-controlled study.
PARTICIPANTS: 49 subjects (76
affected eyes) with an average age of 65.3 +/- 7.0 years with a
diagnosis of senile cataract with minimum to advanced
opacification in various lens layers. METHODS: 26 patients (41
eyes) were allocated to topical NAC 1% eyedrops twice daily.
The control group consisted of 13 patients (21
eyes) who received placebo eyedrops and 10 patients (14 eyes) who
did not receive eyedrops.
MAIN OUTCOME MEASURES: All
patients were evaluated at entry and followed up every 2 months
for a 6-month period (trial 1), or at 6-month intervals for a
2-year period (trial 2), for best-corrected visual acuity and
glare testing. In addition, cataract was measured using
stereocinematographic slit-images and retro-illumination
examination of the lens. Digital analysis of lens images displayed
light scattering and absorbing centres in two- and
three-dimensional scales.
RESULTS: The overall
intra-reader reproducibility of cataract measurements (image
analysis) was 0.830, and glare testing 0.998. After 6 months, 90%
of NAC-treated eyes showed improvement in best corrected visual
acuity (7 to 100%) and 88.9% showed a 27 to 100% improvement in
glare sensitivity.
Topographic studies indicated fewer areas of
posterior subcapsular lens opacity and 41.5% of treated eyes had
improvement in image analysis characteristics. The overall ratios
of image analysis characteristics at 6 months compared with
baseline measures were 1.04 and 0.86 for the control and NAC-treated
group, respectively (p < 0.001). The apparent benefits of
treatment were sustained after 24 months' treatment.
No treated eyes demonstrated worsening of
vision. The overall visual outcome in the control group showed
significant worsening after 24 months in comparison with both
baseline and the 6-month follow-up examination. The overall
clinical results observed in the NAC-treated group by the 24-month
period of examination differed significantly (p < 0.001) from the
control group in the eyes with cortical, posterior subcapsular,
nuclear or combined lens opacities. Tolerability of NAC eyedrops
was good in almost all patients, with no reports of ocular or
systemic adverse effects.
CONCLUSION: Topical NAC shows
potential for the treatment and prevention of cataracts.
Publication Types:
|
| |
Clinical Trial
Randomised Controlled Trial |
|
|
The photographs below show images of a lens with senile cataract
(corticonuclear opacities, grade 4, age 75 years, female), and
the subsequent slit images in optical section documenting in the
focal plane: (a) marked light scattering in the nucleus and
posterior cortical region outlined by the lens optical scanning
with the focal plane movement inside the lens thickness; (b)
light scattering in the anterior subcapsular, anterior cortical
and nuclear regions of the lens; retro-illumination lens images
with a focal plane positioned (c) onto the iris and (d) on the
posterior lens layers. Opacities in the cortical layers are
demonstrated as the white background inclusions in the boundary
of the pupil locally masked by the flashlight article. (e) the
neutral density step reference wedge captured in the plane of
the camera focus and allowing correction for variations in film
development and flashlight output.
|
|
 |
|
In the NAC-treated group, 6-month follow-up showed an
improvement in VA (7-100%) in 37 of the 41 treated eyes and a
significant improvement in glare sensitivity at red and green
targets (27-100%) was documented in 16 of the 18 eyes tested. A
significant improvement in lens clarity was found in 17 of the
41 eyes as documented by a significant decrease of M and H
characteristics during image grading. The NAC-treated eyes had
statistically significant differences in VA, glare sensitivity
and characteristics of image analysis compared with the control
group (p < 0.001) at this time point, as supported by the
overall t-test results of the ratio of the follow-up data to the
baseline values.
|
|
|
Bright Eyes Drops For Pets
